INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,232,000 | 0.0% | 18,590,000 | 0.0% | 0.14% | -12.7% |
| Q4 2021 | $11,232,000 | -8.9% | 18,590,000 | -9.7% | 0.16% | -6.2% |
| Q3 2021 | $12,327,000 | -25.6% | 20,590,000 | -17.6% | 0.18% | +36.4% |
| Q2 2021 | $16,578,000 | – | 25,000,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $34,742,000 | 1.33% |
| PenderFund Capital Management Ltd. | 5,000,000 | $3,839,000 | 0.98% |
| Context Capital Management, LLC | 7,485,000 | $4,494,000 | 0.62% |
| Opti Capital Management, LP | 7,000,000 | $4,250,000 | 0.47% |
| Soros Fund Management | 32,298,000 | $19,611,000 | 0.37% |
| Shaolin Capital Management LLC | 7,000,000 | $4,175,000 | 0.29% |
| Weiss Asset Management LP | 3,500,000 | $2,084,000 | 0.09% |
| CSS LLC/IL | 2,825,000 | $1,681,000 | 0.06% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $137,000 | 0.02% |
| LAZARD ASSET MANAGEMENT LLC | 25,000,000 | $15,009,000 | 0.02% |